Kindeva Drug Delivery Expands Manufacturing Capabilities for Eco-Friendly Inhalers at UK Facility

Kindeva Drug Delivery, a prominent figure in the realm of drug-device combination products, has unveiled its plans to bolster its manufacturing capabilities with a second production line for pressurized metered-dose inhaler (pMDI) products at its facility in Loughborough, U.K. This new line is designed to accommodate low-GWP (Global Warming Potential) propellants, including HFA-152a and HFO-1234ze, boasting GWPs substantially lower than the industry standard HFA-134a. Scheduled for operation in 2026, this addition complements Kindeva’s first pMDI manufacturing line, set to finalize installation later in 2024.

CEO Milton Boyer expressed the significance of this investment, heralding the introduction of one of the largest-volume commercial green propellant lines to the contract manufacturing market, capable of churning out up to 50 million pMDI units annually. Emphasizing Kindeva’s dedication to sustainability, Boyer underscored the importance of maintaining patient choices while advancing environmental objectives. The operationalization of the first GMP low-GWP manufacturing line by 2024 further solidifies Kindeva’s pioneering role in transitioning to low-GWP propellants.

The decision to expand manufacturing capabilities responds to heightened consumer demand for eco-friendly pMDI products and aligns with the recent adoption of F-gas legislation in the European Union. Phase-down procedures for existing propellants within the EU are slated to commence in 2027, culminating by the end of 2029.

Boyer reiterated Kindeva’s legacy in the pMDI arena, spanning nearly seven decades, from the inception of the pMDI in 1956 to spearheading the transition from CFC to HFA inhalers in the 1990s. Positioned at the forefront of the industry-wide shift toward low-GWP propellants, Kindeva aims to contribute to a greener future for all stakeholders.

This announcement signals the next phase of Kindeva’s leadership in driving sustainable innovation within the pMDI landscape and beyond, encompassing complex drug and combination products.

Source Link

Newsletter Updates

Enter your email address below and subscribe to our newsletter